MX355015B - Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal. - Google Patents

Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal.

Info

Publication number
MX355015B
MX355015B MX2014003256A MX2014003256A MX355015B MX 355015 B MX355015 B MX 355015B MX 2014003256 A MX2014003256 A MX 2014003256A MX 2014003256 A MX2014003256 A MX 2014003256A MX 355015 B MX355015 B MX 355015B
Authority
MX
Mexico
Prior art keywords
indolyl
heart failure
neuronal injury
treating heart
hydroxamates
Prior art date
Application number
MX2014003256A
Other languages
English (en)
Other versions
MX2014003256A (es
Inventor
Chen Yi-Jen
Hung Kuo-Sheng
Kao Yu-Hsun
Liou Jing-Ping
Shan Pei-Wen
Original Assignee
Univ Taipei Medical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Taipei Medical filed Critical Univ Taipei Medical
Publication of MX2014003256A publication Critical patent/MX2014003256A/es
Publication of MX355015B publication Critical patent/MX355015B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

El uso novedoso de moléculas pequeñas, particularmente hidroxamatos de indolilo e indolinilo, se da a conocer en este documento. Los hidroxamatos de indolilo e indolinilo son útiles como compuestos de partida para elaborar un medicamento o una composición farmacéutica para tratar a un paciente que adolece de insuficiencia cardiaca o lesión neuronal.
MX2014003256A 2011-09-15 2012-09-15 Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal. MX355015B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161534902P 2011-09-15 2011-09-15
US201161537589P 2011-09-22 2011-09-22
PCT/US2012/055664 WO2013040520A1 (en) 2011-09-15 2012-09-15 Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury

Publications (2)

Publication Number Publication Date
MX2014003256A MX2014003256A (es) 2014-09-15
MX355015B true MX355015B (es) 2018-04-02

Family

ID=47883813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003256A MX355015B (es) 2011-09-15 2012-09-15 Uso de hidroxamatos de indolilo e indolinilo para tratar insuficiencia cardiaca o lesión neuronal.

Country Status (11)

Country Link
US (1) US9296692B2 (es)
EP (1) EP2763673B1 (es)
JP (1) JP6180417B2 (es)
KR (1) KR20140091522A (es)
CN (1) CN104080451B (es)
AU (1) AU2012308243B2 (es)
CA (1) CA2848877A1 (es)
MX (1) MX355015B (es)
RU (1) RU2615767C2 (es)
TW (1) TWI464147B (es)
WO (1) WO2013040520A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI659017B (zh) 2013-11-24 2019-05-11 臺北醫學大學 吲哚基及吲哚啉基異羥肟酸於治療神經退化病症或認知缺乏之用途
HRP20240306T1 (hr) * 2015-10-27 2024-05-10 Taipei Medical University Derivati indolina za liječenje i/ili prevenciju fibroznih bolesti
CN107141247B (zh) * 2017-06-02 2020-03-20 烟台大学 抗心脏衰竭化合物、其制备方法及应用
RU2673481C1 (ru) * 2017-12-11 2018-11-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Юго-Западный государственный университет" (ЮЗГУ) Способ комплексной терапии при сочетанной ишемии центральной гемодинамической системы, нижних конечностей, сердца и головного мозга
EP4019806A4 (en) 2019-08-22 2023-04-19 Harmonic Drive Systems Inc. ONE SHAFT GEAR DEVICE
WO2025238446A1 (en) 2024-05-17 2025-11-20 3M Innovative Properties Company Coating comprising methyl methacrylate copolymer with silicon-oxygen groups and articles

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338755A (en) 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
US5175164A (en) * 1991-06-05 1992-12-29 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted indole or dihydroindole
JP2881688B2 (ja) * 1995-09-27 1999-04-12 小野薬品工業株式会社 スルホンアミド誘導体
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
DE60020786T2 (de) * 1999-09-30 2006-03-23 Pfizer Products Inc., Groton 6-Azauracilderivate als Liganden der Thyroidrezeptoren
JP2001233875A (ja) * 1999-10-12 2001-08-28 Takeda Chem Ind Ltd ピリミジン−５−カルボキサミド化合物、その製造法およびその用途
JP2002371059A (ja) * 2000-05-16 2002-12-26 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
GEP20053675B (en) * 2001-03-30 2005-11-25 Pfizer Prod Inc Pyridazinone Aldose Reductase Inhibitors
EP1753421B1 (en) * 2004-04-20 2012-08-01 Amgen Inc. Arylsulfonamides and uses as hydroxysteroid dehydrogenase
KR101229647B1 (ko) * 2004-09-03 2013-02-05 메르크 세로노 에스.에이. 피리딘 메틸렌 아조리디논 및 포스포이노시타이드 저해제의용도
WO2006038594A1 (ja) * 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. Ｎ型カルシウムチャネル阻害薬
WO2006101456A1 (en) * 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
WO2006117165A2 (en) * 2005-05-02 2006-11-09 Friedrich-Alexander-Universität Erlangen-Nürnberg Means and methods for the treatment of head injuries and stroke
CA2617636A1 (en) * 2005-08-10 2007-02-22 Novartis Ag Use of histone deacetylase inhibitors for treating cardiac hypertrophy and heart failure
GB0526257D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
WO2007084625A2 (en) * 2006-01-19 2007-07-26 Mount Sinai School Of Medicine Novel compounds and methods for inhibiting p53 activity
EP2465850B1 (en) * 2006-02-28 2016-11-23 Dart Neuroscience (Cayman) Ltd Therapeutic compounds
WO2008042795A2 (en) * 2006-09-29 2008-04-10 The Board Of Trustees Of The University Of Illinois Histone acetyle transferase activators and histone deacetylase inhibitors in the treatment of alcoholism
MX2009006327A (es) * 2006-12-15 2009-06-23 Novartis Ag Compuestos heterociclicos y metodos de uso de los mismos.
JP2010513223A (ja) * 2006-12-15 2010-04-30 アステラス製薬株式会社 Ｎ−ヒドロキシアクリルアミド化合物
EP2139852A1 (en) * 2006-12-19 2010-01-06 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
TW201028421A (en) * 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
PL2427436T3 (pl) * 2009-05-07 2013-06-28 Gruenenthal Gmbh Podstawione aromatyczne pochodne karboksamidu i mocznika jako ligandy receptora waniloidowego
US9126938B2 (en) * 2009-08-17 2015-09-08 The Brigham And Women's Hospital, Inc. Phosphatidylcholine transfer protein inhibitors
FR2949278B1 (fr) * 2009-08-18 2012-11-02 Commissariat Energie Atomique Procede de fabrication d'un dispositif d'emission de lumiere a base de diodes electroluminescentes
TWI429628B (zh) * 2010-03-29 2014-03-11 Univ Taipei Medical 吲哚基或吲哚啉基羥肟酸化合物

Also Published As

Publication number Publication date
AU2012308243A8 (en) 2014-05-22
RU2014114860A (ru) 2015-10-20
WO2013040520A1 (en) 2013-03-21
KR20140091522A (ko) 2014-07-21
AU2012308243B2 (en) 2017-09-14
US20150065552A1 (en) 2015-03-05
EP2763673B1 (en) 2018-08-01
US9296692B2 (en) 2016-03-29
CN104080451A (zh) 2014-10-01
TW201313679A (zh) 2013-04-01
RU2615767C2 (ru) 2017-04-11
EP2763673A1 (en) 2014-08-13
CA2848877A1 (en) 2013-03-21
JP2014526518A (ja) 2014-10-06
JP6180417B2 (ja) 2017-08-16
CN104080451B (zh) 2016-08-24
TWI464147B (zh) 2014-12-11
MX2014003256A (es) 2014-09-15
EP2763673A4 (en) 2015-05-06
AU2012308243A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
PH12017501306A1 (en) Inhibitors of histone demethylases
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
PH12014500468A1 (en) Heterocyclic compounds and uses thereof
PH12013502262A1 (en) Spiro-[1,3]-oxazines and spiro-[1,4]-oxazepines as bace1 and/or bace2 inhibitors
HK1198443A1 (en) Heterocyclic compounds and uses thereof
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
PH12013501600A1 (en) Novel heterocyclic derivatives
PH12013502156A1 (en) 1,3-oxazines as bace1 and/or bace2 inhibitors
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
MY174747A (en) Bace1 inhibitors
PT2470199T (pt) Terapia de substituição enzimática com escaladas de dose para tratamento de deficência em esfingomielinase ácida
WO2012100043A3 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
AU2012308243A8 (en) Use of indolyl and indolinyl hydroxamates for treating heart failure of neuronal injury
AU2011322715A8 (en) Treatment of MeCP2-associated disorders
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
WO2016025671A3 (en) Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist
WO2011056850A3 (en) Linaclotide for the treatment of chronic constipation
WO2013038200A3 (en) Neurodevelopmental disorders
BR112013023703A2 (pt) composição tópicas que compreendem diamino oxidase para o tratamento ou prevenção de doenças associadas a altos níveis de histamina que envolvem um aumento da dor

Legal Events

Date Code Title Description
FG Grant or registration